Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667288 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Safety Study of A-101 Solution
A Phase 3 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 147
- Enrollment target
NCT02667288: Completed Phase 3 study, sponsored by Aclaris Therapeutics.
NCT02667288 is a Phase 3 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 147 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02667288, a Phase 3 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 147 participants
- Enrollment target
Study Summary
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
Primary Outcome
Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment (PWA) Scale. The PWA scale is a 4 point scale used by the investigator to assess each subject target SK Lesion.
Interventions
- DRUG A-101 Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
What the finished NCT02667288 record still lists
NCT02667288 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which A-101 Solution is the first listed.
NCT02667288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02667288 about?
NCT02667288 is a clinical study titled "An Open-Label Safety Study of A-101 Solution". This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
What is the current status of trial NCT02667288?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 147 participants. The study started on 2016-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02667288?
The interventions under investigation include: A-101 Solution (DRUG).
Who is sponsoring clinical trial NCT02667288?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02667288's enrollment target sits among peer trials
147 1550th of 2000 higher than 450 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia